Figure 3 | British Journal of Cancer

Figure 3

From: Evaluation of a chemoresponse assay as a predictive marker in the treatment of recurrent ovarian cancer: further analysis of a prospective study

Figure 3

PFS for patients displaying homogeneous vs heterogeneous assay responses. Patients were classified into four groups based on their calculated multiple drug response index (MDRI) and administered clinical treatment: sensitive to all assayed therapies (MDRI=100%) and treated with a sensitive therapy (SA), sensitive to some therapies (0<MDRI<100%) and treated with a sensitive therapy (SP), non-sensitive to all therapies (MDRI=0) and treated with a non-sensitive therapy (RA), and non-sensitive to some therapies (0<MDRI<100%) and treated with a non-sensitive therapy (RP).

Back to article page